# Downregulation of hsa-miR-132 and hsa-miR-129: non-coding RNA molecular signatures of Alzheimer’s disease

## TL;DR

This paper reviews how two specific non-coding RNAs, hsa-miR-132 and hsa-miR-129, are consistently reduced in Alzheimer's disease and may serve as molecular markers for the condition.

## Contribution

The paper identifies a consistent non-coding RNA molecular signature of Alzheimer's disease involving hsa-miR-132 and hsa-miR-129.

## Key findings

- hsa-miR-132 and hsa-miR-129 are consistently downregulated in Alzheimer's disease brains.
- These miRNAs are linked to mRNA targets through computational and sequencing data.
- The downregulation pattern has been observed across 15 years of AD research.

## Abstract

Alzheimer’s disease (AD) affects the elderly population by causing memory impairments, cognitive and behavioral abnormalities. Currently, no curative treatments exist, emphasizing the need to explore therapeutic options that modify the progression of the disease. MicroRNAs (miRNAs), as non-coding RNAs, demonstrate multifaceted targeting potential and are known to be dysregulated in AD pathology. This mini review focuses on two promising miRNAs, hsa-miR-132 and hsa-miR-129, which consistently exhibit differential regulation in AD. By employing computational predictions and referencing published RNA sequencing dataset, we elucidate the intricate miRNA-mRNA target relationships associated with hsa-miR-132 and hsa-miR-129. Our review consistently identifies the downregulation of hsa-miR-132 and hsa-miR-129 in AD brains as a non-coding RNA molecular signature across studies conducted over the past 15 years in AD research.